Sanofi acquires Dynavax for $2.2bn, gaining HEPLISAV-B hepatitis B vaccine. Transaction expected to close in Q1 2026. HEPLISAV-B generated $268.4m in 2024, with projected revenue of $305-325m in 2025. GlobalData forecasts $677m in annual sales by 2031.

CDC changes guidance on newborn hepatitis B vaccine. Medical bodies react to policy shift. Dynavax’s pipeline includes Z-1018 shingles vaccine with promising results. Shingrix by GSK dominates shingles market, generating $3.4bn in 2024 globally.

Sanofi’s acquisition adds hepatitis B and shingles vaccines to portfolio. Company aims to offer vaccine protection across all ages. Analysts view deal positively, citing strategic fit and value creation potential. Sanofi to benefit from Dynavax’s vaccine capabilities and product pipeline.

Read more at Yahoo Finance: Sanofi buys hep B vaccine maker for $2.2bn